MedWatch

Coloplast CEO on buying spree: "Something has to happen"

Medtech firm Coloplast is being encouraged to put some of its billions to use, and CEO Kristian Villumsen sort of agrees. But not at any cost.

Photo: Stine Bidstrup/ERH

They've had plenty of bullets, but so far no wish to pull the trigger. Lucrative medtech firm Coloplast is technically on a buying spree, firstly and foremostly in order to strengthen its urology business leg, which needs scale.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs